Biosimilars – Forecast – Oncology
In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion. Throughout the 2024-2034 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Oncology MAb Forecasts
- G-CSF Forecasts
- Key takeaways
- Overview
- Drug-Specific Forecast Assumptions
Related Market Assessment Reports
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
AMD is a leading cause of vision loss across the G7 markets, with wet AMD accounting for most drug-treated cases. The market is dominated by IVT therapies such as Avastin, Eylea, Vabysmo, and Eylea…
Report
Immune Thrombocytopenic Purpura – Unmet Need – Unmet Need – Immune Thrombocytopenic Purpura (US/EU)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening…
Report
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current Treatment – Current Treatment: Physician Insights – Neuromyelitis Optica Spectrum Disorder (US)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic autoimmune neuroinflammatory disorder marked by optic neuritis and longitudinally extensive transverse myelitis, often leading to…
